Ozempic

Doctors are warning that people taking GLP-1 weight-loss and diabetes drugs such as Ozempic may face heightened health risks during the current heat wave. Concerns center on dehydration, as the medications can suppress thirst and appetite, potentially leaving users vulnerable to heat exhaustion and related complications. Patients are being advised to drink water regularly and take precautions in high temperatures as extreme heat persists across many regions.

A new study reports that about one in six children taking GLP-1 medications, such as Ozempic and Wegovy, developed nutritional deficiencies while on the drugs. The findings raise concerns that appetite suppression and reduced intake may leave some children short on key nutrients, prompting calls for closer monitoring of children prescribed these increasingly used weight-loss medications.

An obesity medicine doctor is addressing growing interest in microdosing Ozempic, the practice of taking very low doses of the weight-loss drug to limit side effects and cost. The doctor explains the possible risks, why unsupervised low dosing can be problematic, and the limited situations where a reduced dose may actually make medical sense.

Public health coverage is drawing together two related topics: the possible mental health effects of GLP-1 weight-loss and diabetes drugs, and the role of exercise for women going through menopause. Listeners are weighing reported mood changes linked to GLP-1 medications against growing evidence that physical activity can ease menopause symptoms such as hot flashes, sleep problems and weight gain.